Praticò D, Barry O P, Lawson J A, Adiyaman M, Hwang S W, Khanapure S P, Iuliano L, Rokach J, FitzGerald G A
Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia, PA 19104-6100, USA.
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3449-54. doi: 10.1073/pnas.95.7.3449.
Isoprostanes are prostaglandin isomers produced from arachidonic acid by a free radical-catalyzed mechanism. Urinary excretion of 8-iso-prostaglandin F2alpha, an isomer of the PGG/H synthase (cyclooxygenase or COX) enzyme product, prostaglandin F2alpha (PGF2alpha), has exhibited promise as an index of oxidant stress in vivo. We have developed a quantitative method to measure isoprostane F2alpha-I, (IPF2alpha-I) a class I isomer (8-iso-PGF2alpha is class IV), using gas chromatography/mass spectrometry. IPF2alpha-I is severalfold as abundant in human urine as 8-iso-PGF2alpha, with mean values of 737 +/- 20.6 pg/mg creatinine. Both isoprostanes are formed in a free radical-dependent manner in low density lipoprotein oxidized by copper in vitro. However, IPF2alpha-I, unlike 8-iso-PGF2alpha, is not formed in a COX-dependent manner by platelets activated by thrombin or collagen in vitro. Similarly, COX inhibition in vivo has no effect on IPF2alpha-I. Neither serum IPF2alpha-I, an index of cellular capacity to generate the isoprostane, nor urinary excretion of IPF2alpha-I, an index of actual generation in vivo, is depressed by aspirin or indomethacin. In contrast, both serum thromboxane B2 and urinary excretion of its 11-dehydro metabolite are depressed by the COX inhibitors. Although serum 8-iso-PGF2alpha formation is substantially depressed by COX inhibitors, urinary excretion of the compound is unaffected. Urinary IPF2alpha-I is elevated in cigarette smokers compared with controls (1525 +/- 180 versus 740 +/- 40 pg/mg creatinine; P < 0.01) and is highly correlated with urinary 8-iso-PGF2alpha (r = 0.9; P < 0.001). Urinary IPF2alpha-I is a novel index of lipid peroxidation in vivo, which can be measured with precision and sensitivity. It is an abundant F2-isoprostane formed in a free radical- but not COX-dependent manner. Although 8-iso-PGF2alpha may be formed as a minor product of COX, this pathway contributes trivially, if at all, to levels in urine. Urinary excretion of both isoprostanes is elevated in cigarette smokers.
异前列腺素是由花生四烯酸通过自由基催化机制产生的前列腺素异构体。8-异前列腺素F2α是PGG/H合酶(环氧化酶或COX)酶产物前列腺素F2α(PGF2α)的一种异构体,其尿排泄量已显示出有望作为体内氧化应激的指标。我们开发了一种定量方法,使用气相色谱/质谱法来测量异前列腺素F2α-I(IPF2α-I,I类异构体,8-异-PGF2α为IV类)。IPF2α-I在人尿中的含量是8-异-PGF2α的几倍,平均值为737±20.6 pg/mg肌酐。在体外被铜氧化的低密度脂蛋白中,这两种异前列腺素均以自由基依赖的方式形成。然而,与8-异-PGF2α不同,IPF2α-I在体外不会由凝血酶或胶原激活的血小板以COX依赖的方式形成。同样,体内COX抑制对IPF2α-I没有影响。阿司匹林或吲哚美辛既不会降低血清IPF2α-I(细胞产生异前列腺素能力的指标),也不会降低其尿排泄量(体内实际产生的指标)。相比之下,COX抑制剂会降低血清血栓素B2及其11-脱氢代谢产物的尿排泄量。虽然COX抑制剂会显著降低血清8-异-PGF2α的形成,但该化合物的尿排泄量不受影响。与对照组相比,吸烟者的尿IPF2α-I升高(1525±180对740±40 pg/mg肌酐;P<0.01),且与尿8-异-PGF2α高度相关(r = 0.9;P<0.001)。尿IPF2α-I是体内脂质过氧化的一个新指标,能够精确且灵敏地进行测量。它是一种大量存在的F2异前列腺素,以自由基而非COX依赖的方式形成。虽然8-异-PGF2α可能作为COX的次要产物形成,但该途径对尿中水平的贡献即使有也微不足道。吸烟者这两种异前列腺素的尿排泄量均升高。